Future dose-ranging and reaccumulation studies in the GLB1 KO mouse model will help to titrate the ICV-ERT dose and dosing frequency for rhβ-gal in clinical trials for GM1 gangliosidosis patients. Here, GLB1 is linked to GM1 gangliosidosis.